Corcept Therapeutics Incorporated (CORT)
Market Closed
3 Jun, 20:00
$
72. 65
+1.45
+2.0365%
$
7.16B Market Cap
- P/E Ratio
- Div Yield
782,105 Volume
- Eps
$ 71.2
Previous Close 
Want to track CORT and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Corcept (CORT) Rises as Cushing's Syndrome Study Meets Goal
Corcept's (CORT) phase III GRACE study, evaluating its lead candidate, relacorilant, for treating patients with Cushing's syndrome, meets the primary endpoint in a randomized withdrawal phase.
Zacks | 2 years ago
